Group 1 - The first sublingual nerve stimulation implant surgery in China was successfully completed, marking a significant advancement in the treatment of obstructive sleep apnea (OSA) [1] - The surgery was performed by a multidisciplinary team and resulted in a notable reduction in breathing pauses and improvement in sleep quality for the patient [1] - This procedure represents a new direction in clinical applications of neural interfaces, potentially driving the development of sleep medicine, wearable monitoring, and rehabilitation management industries [1] Group 2 - Haizheng Pharmaceutical signed an exclusive licensing and strategic cooperation agreement with Aixin Dawei to introduce the first-in-class small molecule prodrug AST-3424 in China [2] - The collaboration aims to enhance Haizheng's innovative drug portfolio and leverage Aixin Dawei's promising research pipeline, potentially accelerating the introduction of new cancer treatment options [2] Group 3 - Renfu Pharmaceutical's subsidiary received a drug registration certificate for "Levonorgestrel Tablets" from the National Medical Products Administration [3] - The approval is significant as it addresses the stable demand for emergency contraceptives, enhancing Renfu's product line and competitive position in the women's health medication market [3] Group 4 - Dairui Biotechnology's clinical trial application for RN3161, a GalNAc-siRNA targeting INHBE, has been accepted in Australia [4] - RN3161 aims to provide a long-term weight loss solution for overweight and obese individuals, addressing urgent treatment needs and filling a market gap left by existing GLP-1 drugs [4] Group 5 - New Element Pharmaceuticals submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [5] - The company focuses on developing therapies for metabolic, inflammatory, and cardiovascular diseases, with a promising product pipeline that includes ABP-671 and ABP-745 [5] - The listing is expected to accelerate research and market expansion, although the industry is highly competitive and poses significant development risks [5]

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has signed an exclusive licensing and strategic cooperation agreement with Shenzhen Aixin Dawei Pharmaceutical Technology Co., Ltd. to enhance its innovation drug development capabilities and create new value growth points [1][3]. Group 1: Licensing Agreement - The agreement grants Haizheng exclusive rights to the globally innovative small molecule prodrug AST-3424 within the specified regions, including mainland China, Hong Kong, and Macau [1]. - Haizheng is authorized to research, develop, register, produce, and commercialize the licensed product, and will be the sole applicant for market approval in the cooperation area [1][3]. - A non-competition clause prohibits Aixin Dawei and its affiliates from engaging in competitive activities in the cooperation area during the agreement's term [2]. Group 2: Financial Terms - Haizheng will pay an upfront fee and milestone payments totaling no more than 240 million RMB based on the achievement of development milestones [3]. - Upon the product's first approval for sale in the cooperation area, Haizheng will pay annual royalties based on a percentage of net sales and milestone bonuses based on annual sales performance [4]. Group 3: Strategic Cooperation on AKR1C3 Enzyme Activation Platform - The agreement includes a strategic cooperation on Aixin Dawei's AKR1C3 enzyme activation platform, with a two-year option period for Haizheng to exercise its rights [5]. - Aixin Dawei is responsible for developing specified drugs using the AKR1C3 platform and advancing them to obtain clinical trial approval in mainland China [5]. - Any intellectual property developed during the cooperation will be exclusively owned or licensed to Haizheng [5][6]. Group 4: Charitable Donation - Haizheng's subsidiary, Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd., will donate 200,000 RMB to support a prostate screening charity project in Nanjing [7]. - The donation is made from the company's own funds and does not significantly impact current or future performance [7].

Group 1 - The core point of the article is that Haizheng Pharmaceutical announced a strategic partnership with Shenzhen Aixin Dawei Pharmaceutical Technology Co., Ltd. through a product exclusive licensing agreement [1] - The company's revenue composition for the year 2024 is as follows: pharmaceutical production accounts for 58.46%, drug sales for 39.29%, other industries for 1.94%, other businesses for 0.23%, and CMO/CDMO/CRO business for 0.08% [1] - As of the report, Haizheng Pharmaceutical has a market capitalization of 12.5 billion yuan [1]

证券代码：600267 证券简称：海正药业 公告编号：临 2025-55 号 浙江海正药业股份有限公司 第十届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"或"海正药业"）第十届 董事会第七次会议于 2025 年 9 月 16 日上午以通讯方式召开，应参加本次会议董 事 9 人，亲自参加会议董事 9 人。本次会议的召开程序符合《公司法》和《公司 章程》的规定，会议合法有效。本次会议由公司董事长肖卫红先生主持，与会董 事以通讯表决方式通过了如下决议： 一、关于公司与深圳艾欣达伟医药科技有限公司签署产品独家许可及战略合 作协议的议案； 为进一步完善公司在创新药领域的战略布局，持续强化创新药开发能力，助 力公司培育新的价值增长点，同意公司引进由深圳艾欣达伟医药科技有限公司 （以下简称"艾欣达伟"）开发的全球首创（FIC）小分子前药 AST-3424（即"合 作标的"，包括其所有规格、剂型及适应症）在合作区域内（指中国大陆、中国 香港特别行政区和中国澳门特别行政区） ...

Core Viewpoint - The company, Haizheng Pharmaceutical (600267.SH), has signed an exclusive licensing and strategic cooperation agreement with Shenzhen Aixin Dawei Pharmaceutical Technology Co., Ltd. to introduce the globally innovative small molecule prodrug AST-3424 in specified regions [1] Group 1 - The company will pay an upfront fee to Aixin Dawei and will also pay milestone payments based on the actual achievement of development milestones, with total costs not exceeding 240 million yuan [1] - The cooperation area includes mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region [1] - The company will also engage in strategic cooperation with Aixin Dawei on the AKR1C3 enzyme activation platform [1]

Core Viewpoint - The article highlights the recognition of Hai Zheng Animal Health's product, Hai Le Miao, as the leading brand in the cat internal deworming market in China, emphasizing its significant market position and consumer acceptance [1][12]. Company Overview - Hai Le Miao is a subsidiary of Zhejiang Hai Zheng Animal Health Products Co., Ltd., which is a holding company of Zhejiang Hai Zheng Pharmaceutical Co., Ltd. (stock code: 600267). The company has invested 800 million to build an international animal health enterprise and has established two major production bases [5][6]. Product Development and Market Position - Hai Le Miao has been awarded certificates for being the "national sales leader in cat internal deworming" and for having "over ten million choices by pet owners," indicating its strong market presence [1][12]. - The product is recognized for its effective formulation, combining Milbemycin Oxime and Praziquantel, which targets eight common internal parasites in cats, making it a preferred choice among cat owners [8][12]. Industry Trends - The demand for cat internal deworming products has evolved from optional to essential, as pet owners increasingly view deworming as a critical aspect of health management, akin to vaccinations and health check-ups [8]. - The regulatory environment for the pet pharmaceutical industry in China is becoming more standardized, leading to increased compliance and quality in production, which benefits leading brands like Hai Le Miao [9][10]. Marketing Strategy - The company employs a dual-channel marketing strategy, focusing on both professional channels (veterinary institutions and large distributors) and consumer channels (e-commerce and social media), enhancing brand recognition and consumer engagement [11]. - Hai Le Miao's marketing efforts have resulted in a strong reputation and consumer loyalty, contributing to its leading market position [11].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、CEP证书相关信息 药品名称：TIGECYCLINE/替加环素 本次公司替加环素原料药获得CEP认证证书，显示欧洲规范市场对该原料药质量的认可和肯定，标志此 产品具备以原料药形式进入欧盟及承认CEP证书的其他市场的资质，为公司进一步拓展国际市场带来积 极的影响。 国际原料药业务易受海外市场环境变化、汇率波动等因素影响，敬请广大投资者理性投资，注意投资风 险。 近日，浙江海正药业股份有限公司（以下简称"公司"）收到欧洲药品质量管理局（European Directorate for the Quality of Medicines & HealthCare，以下简称"EDQM"）签发的替加环素原料药欧洲药典适用性 认证证书（Certificate of Suitability to Monograph of European Pharmacopoeia，以下简称"CEP证书"），现 就相关情况公告如下： 产品剂型：原料药 证书编号：No. CEP 2024-176 - Rev ...

证券代码：600267 证券简称：海正药业 公告编号：临 2025-54 号 浙江海正药业股份有限公司 关于替加环素原料药获得 CEP 证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江海正药业股份有限公司（以下简称"公司"）收到欧洲药品质量 管理局（European Directorate for the Quality of Medicines & HealthCare，以下简称 "EDQM"）签发的替加环素原料药欧洲药典适用性认证证书（Certificate of Suitability to Monograph of European Pharmacopoeia，以下简称"CEP 证书"）， 现就相关情况公告如下： 一、CEP证书相关信息 特此公告。 生产地址：浙江省台州市椒江区外沙路46号 发证机构：欧洲药品质量管理局（EDQM） 二、药品的其他相关情况 替加环素主要适用于18岁以上患者在下列情况下由特定细菌的敏感菌株所 致感染的治疗：复杂性腹腔内感染、复杂性皮肤和皮肤软组织感染、社区获得性 细菌 ...

替加环素主要适用于18岁以上患者在下列情况下由特定细菌的敏感菌株所致感染的治疗：复杂性腹腔内 感染、复杂性皮肤和皮肤软组织感染、社区获得性细菌性肺炎。 格隆汇9月12日丨海正药业(600267.SH)公布，公司收到欧洲药品质量管理局（European Directorate for the Quality of Medicines & HealthCare，简称"EDQM"）签发的替加环素原料药欧洲药典适用性认证证书 （Certificate ofSuitability to Monograph of European Pharmacopoeia，简称"CEP 证书"）。 ...

Core Viewpoint - Haizheng Pharmaceutical has received the CEP certificate for Tigecycline raw materials from the European Medicines Agency, marking it as the first domestic company to achieve this certification, which enhances its qualifications for entering the EU and other markets that recognize the CEP certificate [1] Group 1 - The receipt of the CEP certificate signifies recognition and affirmation of the quality of the raw material by the European regulatory market [1] - This certification allows the company to expand its international market presence positively [1]